Symbols / APRE $0.95 +4.70% Aprea Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
APRE Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Fundamentals
Scroll to Statements
Market Cap 10.88M Enterprise Value -3.48M Income -12.60M Sales 285.76K Book/sh 1.52 Cash/sh 1.27
Dividend Yield — Payout 0.00% Employees 8 IPO — P/E — Forward P/E -1.44
PEG — P/S 38.07 P/B 0.63 P/C — EV/EBITDA 0.26 EV/Sales -12.18
Quick Ratio 5.28 Current Ratio 5.63 Debt/Eq — LT Debt/Eq — EPS (ttm) -1.93 EPS next Y -0.66
EPS Growth — Revenue Growth -98.40% Earnings 2026-03-16 ROA -41.45% ROE -74.58% ROIC —
Gross Margin 0.00% Oper. Margin -792.06% Profit Margin 0.00% Shs Outstand 11.45M Shs Float 8.78M Short Float 5.93%
Short Ratio 1.16 Short Interest — 52W High 2.22 52W Low 0.55 Beta 1.57 Avg Volume 2.39M
Volume 143.61K Target Price $4.40 Recom Strong_buy Prev Close $0.91 Price $0.95 Change 4.70%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$4.40
Mean price target
2. Current target
$0.95
Latest analyst target
3. DCF / Fair value
$-13.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.95
Low
$1.20
High
$7.00
Mean
$4.40

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-31 reit Wedbush Outperform → Outperform $7
2026-03-31 main HC Wainwright & Co. Buy → Buy $1
2026-02-10 main Wedbush Outperform → Outperform $7
2026-01-29 main HC Wainwright & Co. Buy → Buy $4
2025-12-18 main HC Wainwright & Co. Buy → Buy $5
2025-01-15 reit HC Wainwright & Co. Buy → Buy $20
2024-12-17 reit HC Wainwright & Co. Buy → Buy $20
2024-11-18 reit HC Wainwright & Co. Buy → Buy $20
2024-10-24 reit HC Wainwright & Co. Buy → Buy $20
2024-08-13 reit Wedbush Outperform → Outperform $11
2024-08-12 reit HC Wainwright & Co. Buy → Buy $20
2024-06-24 reit HC Wainwright & Co. Buy → Buy $20
2024-06-17 reit HC Wainwright & Co. Buy → Buy $20
2024-05-14 reit HC Wainwright & Co. Buy → Buy $20
2024-03-27 main Wedbush Outperform → Outperform $11
2024-03-26 main HC Wainwright & Co. Buy → Buy $20
2023-11-01 reit HC Wainwright & Co. Buy → Buy $20
2023-09-13 reit HC Wainwright & Co. Buy → Buy $20
2023-08-10 reit HC Wainwright & Co. Buy → Buy $20
2023-05-16 reit HC Wainwright & Co. Buy → Buy $20
News
RSS: Latest APRE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-12 HAMILL JOHN P Chief Financial Officer — 10,095 $0.00 $0
2026-03-12 GILAD OREN PH.D. Chief Executive Officer — 20,175 $0.00 $0
2026-01-30 HAMILL JOHN P Chief Financial Officer — 5,700 $0.89 $5,073
2026-01-30 GILAD OREN PH.D. Chief Executive Officer — 28,100 $0.89 $25,009
2025-12-10 HAMILL JOHN P Chief Financial Officer — 5,000 $0.91 $4,561
2025-12-10 DUEY MARC Director — 21,459 $0.91 $19,575
2025-06-05 PAMAKCU RIFAT Director — 1,045 $0.00 $0
2025-06-05 HENNEMAN JOHN BELL III Director — 1,045 $0.00 $0
2025-06-05 BIZZARI JEAN-PIERRE Director — 1,045 $0.00 $0
2025-06-05 PETERS RICHARD Director — 1,045 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
13.23
-7.58%
14.32
-7.45%
15.47
-58.60%
37.37
Research And Development
7.04
-24.78%
9.36
+22.76%
7.63
-53.50%
16.40
Selling General And Administration
6.48
+0.28%
6.46
-23.36%
8.43
-59.81%
20.97
General And Administrative Expense
6.48
+0.28%
6.46
-23.36%
8.43
-59.81%
20.97
Other Gand A
6.48
+0.28%
6.46
-23.36%
8.43
-59.81%
20.97
Other Operating Expenses
-0.29
+80.98%
-1.50
-157.63%
-0.58
—
Total Expenses
13.23
-7.58%
14.32
-7.45%
15.47
-58.60%
37.37
Operating Income
-13.23
+7.58%
-14.32
+7.45%
-15.47
+58.60%
-37.37
Total Operating Income As Reported
-13.23
+7.58%
-14.32
+7.45%
-15.47
+86.36%
-113.39
EBITDA
-13.21
+7.59%
-14.30
+7.55%
-15.46
+58.41%
-37.19
Normalized EBITDA
-13.12
+8.72%
-14.37
+6.85%
-15.43
-140.01%
38.55
Reconciled Depreciation
0.02
-2.70%
0.02
+216.48%
0.01
-96.22%
0.19
EBIT
-13.23
+7.58%
-14.32
+7.45%
-15.47
+58.60%
-37.37
Total Unusual Items
-0.10
-232.76%
0.07
+284.45%
-0.04
+99.95%
-75.74
Total Unusual Items Excluding Goodwill
-0.10
-232.76%
0.07
+284.45%
-0.04
+99.95%
-75.74
Special Income Charges
—
—
0.00
+100.00%
-76.02
Other Special Charges
—
—
—
76.02
Net Income
-12.60
+2.77%
-12.96
+9.30%
-14.29
+87.32%
-112.66
Pretax Income
-12.60
+2.77%
-12.96
+9.30%
-14.29
+87.32%
-112.66
Net Non Operating Interest Income Expense
0.65
-49.42%
1.29
+5.31%
1.22
+172.84%
0.45
Net Interest Income
0.65
-49.42%
1.29
+5.31%
1.22
+172.84%
0.45
Interest Income Non Operating
0.65
-49.42%
1.29
+5.31%
1.22
+172.84%
0.45
Interest Income
0.65
-49.42%
1.29
+5.31%
1.22
+172.84%
0.45
Other Income Expense
-0.02
-124.82%
0.07
+284.45%
-0.04
+99.95%
-75.74
Other Non Operating Income Expenses
0.08
—
—
—
Gain On Sale Of Security
-0.10
-232.76%
0.07
+284.45%
-0.04
-113.83%
0.28
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-12.60
+2.77%
-12.96
+9.30%
-14.29
+87.32%
-112.66
Net Income From Continuing Operation Net Minority Interest
-12.60
+2.77%
-12.96
+9.30%
-14.29
+87.32%
-112.66
Net Income From Continuing And Discontinued Operation
-12.60
+2.77%
-12.96
+9.30%
-14.29
+87.32%
-112.66
Net Income Continuous Operations
-12.60
+2.77%
-12.96
+9.30%
-14.29
+87.32%
-112.66
Normalized Income
-12.50
+4.04%
-13.03
+8.54%
-14.25
+61.41%
-36.92
Net Income Common Stockholders
-12.60
+2.77%
-12.96
+9.30%
-14.29
+87.32%
-112.66
Diluted EPS
—
-2.35
+40.51%
-3.95
+94.19%
-67.99
Basic EPS
—
-2.35
+40.51%
-3.95
+94.19%
-67.99
Basic Average Shares
—
5.51
+52.31%
3.62
+118.32%
1.66
Diluted Average Shares
—
5.51
+52.31%
3.62
+118.32%
1.66
Diluted NI Availto Com Stockholders
-12.60
+2.77%
-12.96
+9.30%
-14.29
+87.32%
-112.66
Total Other Finance Cost
—
—
—
-0.45
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
15.93
-33.55%
23.98
+5.87%
22.65
-24.89%
30.16
Current Assets
15.56
-34.00%
23.58
+4.68%
22.52
-25.31%
30.15
Cash Cash Equivalents And Short Term Investments
14.60
-36.11%
22.85
+5.75%
21.61
-24.94%
28.79
Cash And Cash Equivalents
14.60
-36.11%
22.85
+5.75%
21.61
-24.94%
28.79
Prepaid Assets
—
—
—
—
Other Current Assets
0.96
+32.45%
0.73
-20.57%
0.91
-33.11%
1.37
Total Non Current Assets
0.37
-7.73%
0.40
+212.49%
0.13
+5461.35%
0.00
Net PPE
0.06
-26.64%
0.08
-7.74%
0.09
+3707.07%
0.00
Gross PPE
0.15
+0.00%
0.15
+11.18%
0.14
+205.09%
0.05
Accumulated Depreciation
-0.09
-29.98%
-0.07
-44.53%
-0.05
-16.37%
-0.04
Machinery Furniture Equipment
0.01
+0.00%
0.01
+0.00%
0.01
+0.00%
0.01
Other Properties
0.15
+0.00%
0.15
+11.62%
0.13
+231.96%
0.04
Other Non Current Assets
0.31
-2.95%
0.32
+690.41%
0.04
—
Total Liabilities Net Minority Interest
3.49
-25.26%
4.67
-17.99%
5.70
+26.25%
4.51
Current Liabilities
2.76
-17.75%
3.36
-23.36%
4.39
+37.00%
3.20
Payables And Accrued Expenses
1.99
-31.15%
2.90
+1.98%
2.84
+57.49%
1.80
Payables
0.71
-47.22%
1.35
-19.05%
1.67
+98.20%
0.84
Accounts Payable
0.71
-47.22%
1.35
-19.05%
1.67
+98.20%
0.84
Current Accrued Expenses
1.28
-17.08%
1.54
+32.02%
1.17
+21.76%
0.96
Pensionand Other Post Retirement Benefit Plans Current
0.77
+65.71%
0.47
-54.27%
1.02
-27.25%
1.40
Current Debt And Capital Lease Obligation
—
—
—
—
Current Capital Lease Obligation
—
—
—
0.00
Current Deferred Liabilities
—
0.00
-100.00%
0.53
0.00
Current Deferred Revenue
—
0.00
-100.00%
0.53
0.00
Total Non Current Liabilities Net Minority Interest
0.73
-44.52%
1.31
+0.00%
1.31
+0.00%
1.31
Long Term Debt And Capital Lease Obligation
—
—
—
0.00
Long Term Capital Lease Obligation
—
—
—
0.00
Preferred Securities Outside Stock Equity
0.73
-44.52%
1.31
+0.00%
1.31
+0.00%
1.31
Stockholders Equity
12.44
-35.56%
19.31
+13.88%
16.95
-33.89%
25.64
Common Stock Equity
12.44
-35.56%
19.31
+13.88%
16.95
-33.89%
25.64
Capital Stock
0.01
+49.46%
0.01
+46.71%
0.00
+40.72%
0.00
Common Stock
0.01
+49.46%
0.01
+46.71%
0.00
+40.72%
0.00
Share Issued
8.19
+49.47%
5.48
+46.68%
3.74
+40.73%
2.66
Ordinary Shares Number
8.19
+49.47%
5.48
+46.68%
3.74
+40.73%
2.66
Additional Paid In Capital
356.71
+1.64%
350.97
+4.57%
335.64
+1.69%
330.06
Retained Earnings
-333.64
-3.92%
-321.04
-4.21%
-308.08
-4.86%
-293.80
Gains Losses Not Affecting Retained Earnings
-10.63
-0.07%
-10.63
-0.15%
-10.61
+0.11%
-10.62
Other Equity Adjustments
-10.63
-0.07%
-10.63
-0.15%
-10.61
+0.11%
-10.62
Total Equity Gross Minority Interest
12.44
-35.56%
19.31
+13.88%
16.95
-33.89%
25.64
Total Capitalization
12.44
-35.56%
19.31
+13.88%
16.95
-33.89%
25.64
Working Capital
12.80
-36.70%
20.22
+11.47%
18.14
-32.71%
26.95
Invested Capital
12.44
-35.56%
19.31
+13.88%
16.95
-33.89%
25.64
Total Debt
—
—
—
0.00
Capital Lease Obligations
—
—
—
0.00
Net Tangible Assets
12.44
-35.56%
19.31
+13.88%
16.95
-33.89%
25.64
Tangible Book Value
12.44
-35.56%
19.31
+13.88%
16.95
-33.89%
25.64
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-12.89
+4.89%
-13.56
-11.32%
-12.18
+51.31%
-25.01
Cash Flow From Continuing Operating Activities
-12.89
+4.89%
-13.56
-11.32%
-12.18
+51.31%
-25.01
Net Income From Continuing Operations
-12.60
+2.77%
-12.96
+9.30%
-14.29
+87.32%
-112.66
Depreciation Amortization Depletion
0.02
-2.70%
0.02
+216.48%
0.01
-96.22%
0.19
Depreciation
—
—
0.01
-96.22%
0.19
Depreciation And Amortization
0.02
-2.70%
0.02
+216.48%
0.01
-96.22%
0.19
Other Non Cash Items
0.04
+123.97%
0.02
—
72.52
Stock Based Compensation
0.48
-2.31%
0.49
+10.12%
0.44
-97.38%
16.98
Operating Gains Losses
0.10
+232.76%
-0.07
-284.45%
0.04
+113.83%
-0.28
Net Foreign Currency Exchange Gain Loss
0.10
+232.76%
-0.07
-284.45%
0.04
+113.83%
-0.28
Change In Working Capital
-0.93
+11.97%
-1.06
-165.20%
1.62
+192.05%
-1.76
Change In Prepaid Assets
-0.22
-125.40%
-0.10
-121.39%
0.45
-79.36%
2.19
Change In Payables And Accrued Expense
-0.71
-65.49%
-0.43
-167.39%
0.64
+116.95%
-3.76
Change In Accrued Expense
-0.06
+44.19%
-0.12
+39.10%
-0.19
+93.47%
-2.90
Change In Payable
-0.65
-105.82%
-0.31
-137.97%
0.83
+196.38%
-0.86
Change In Account Payable
-0.65
-105.82%
-0.31
-137.97%
0.83
+196.38%
-0.86
Change In Other Working Capital
—
-0.53
-200.00%
0.53
—
Change In Other Current Liabilities
—
—
0.00
+100.00%
-0.19
Investing Cash Flow
0.00
+100.00%
-0.02
+83.37%
-0.09
0.00
Cash Flow From Continuing Investing Activities
0.00
+100.00%
-0.02
+83.37%
-0.09
0.00
Net PPE Purchase And Sale
0.00
+100.00%
-0.02
+83.37%
-0.09
0.00
Purchase Of PPE
0.00
+100.00%
-0.02
+83.37%
-0.09
0.00
Capital Expenditure
—
-0.02
+83.37%
-0.09
—
Financing Cash Flow
4.64
-68.69%
14.82
+188.36%
5.14
+652.59%
0.68
Cash Flow From Continuing Financing Activities
4.64
-68.69%
14.82
+188.36%
5.14
+652.59%
0.68
Net Common Stock Issuance
5.05
-68.73%
16.14
+178.81%
5.79
+747.61%
0.68
Proceeds From Stock Option Exercised
0.00
0.00
0.00
0.00
Net Other Financing Charges
-0.41
+69.10%
-1.32
-103.18%
-0.65
—
Changes In Cash
-8.25
-760.50%
1.25
+117.53%
-7.13
+70.69%
-24.33
Effect Of Exchange Rate Changes
0.00
+165.16%
-0.01
+14.50%
-0.01
-121.67%
0.04
Beginning Cash Position
22.89
+5.74%
21.65
-24.80%
28.79
-45.76%
53.08
End Cash Position
14.64
-36.04%
22.89
+5.74%
21.65
-24.80%
28.79
Free Cash Flow
-12.89
+4.99%
-13.57
-10.61%
-12.27
+50.94%
-25.01
Common Stock Issuance
5.05
-68.73%
16.14
+178.81%
5.79
+747.61%
0.68
Issuance Of Capital Stock
5.05
-68.73%
16.14
+178.81%
5.79
+747.61%
0.68
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category